Kaempferol

Where the papers sit

16 papers from the last 6 months study kaempferol directly · updated from PubMed 10 Oct 2026

• Inflammation and Cell Death

  Kaempferol research is moving toward pathway-directed treatment of inflammatory, degenerative, and therapy-related injury. NLRP3/caspase-1/GSDMD pyroptosis, BAX-linked apoptosis, IL-1β, and AKT-mTOR glycolysis recur as mechanistic targets. Selenium nanoparticles, solid lipid nanoparticles, polymer carriers, and extracellular vesicles are used to improve delivery or tissue selectivity. Single-cell profiling and network pharmacology are expanding target discovery, but disease contexts and endpoints remain heterogeneous.

  8 papers · 50%

• Natural Product Therapeutics

  Natural-product work is moving from antioxidant screening toward mechanism-based intervention across cancer, infection, inflammation, and neurodegeneration. Docking and molecular dynamics recur alongside cellular or proteomic validation, while ACSL4/COX-2 lipid peroxidation and nuclear transport are specific mechanistic anchors. Formulation studies extend this approach to edaravone–kaempferol nanoparticles and antioxidant creams. The indications remain too diverse to establish a unified therapeutic direction.

  6 papers · 37.5%

• Antioxidant Tissue Protection

  Antioxidant delivery is being used to protect vulnerable tissues from oxidative injury, with reactive oxygen species and superoxide as recurring targets. In semen preservation, liposomal lipophilic antioxidants aim to maintain plasma-membrane integrity and sperm motility during storage. In oral repair, a self-healing PF127-gelatin sealant adds antioxidant and antibacterial activity to accelerate ulcer closure. The small set supports local biomaterial delivery more than a general clinical efficacy conclusion.

  2 papers · 12.5%